US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo publishes the Annual and Sustainability Report for 2022

    Uppsala, Sweden - March 28, 2023 – Orexo’s Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish in accordance with the European Single Electronic Format (ESEF). A PDF version of the report is attached to this press release.   Nikolaj Sørensen, President and CEO: “By finalizing the development of OX124, and launching MODIA®, we have improved Orexo’s offering for opioid dependent patients. Our strengthened position means that we are ready to benefit from the deregulation for physicians to treat

    Orexo publishes Annual Report for 2020

    Uppsala, Sweden - March 23, 2021 – Orexo’s Annual Report for the 2020 fiscal year has been published. The Annual Report can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts), and a PDF is also attached to this press release. “Despite a challenging year with Covid-19 we took several important steps in our ambition to diversify the business. The product portfolio was expanded with world-leading digital therapies and our flagship pharma project, OX124, progressed according to plan. With a strong financial position and continued robust

    Orexo publishes the Annual Report for 2019

    Uppsala, Sweden - March 26, 2020 – Orexo’s Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts), and a PDF is also attached to this press release.   In regards to ESMA´s recommendations the Report also includes the operational and financial impact the company sees due to COVID-19 (CEO Comments, Board of Directors Report and Note 34), which still is in line with earlier communicated information within this field. Orexo

    Orexo publishes the Annual Report for 2018

    Uppsala, Sweden - March 21, 2019 – Orexo’s Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts). A PDF version is also attached to this press release. For further information, please contact: Orexo AB (publ.) Lena Wange, IR & Communications Manager            Tel: +46 18 780 88 00e-mail: ir@orexo.com About OrexoOrexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily

    Orexo’s annual report for 2014 released

    Orexo’s annual report for the 2014 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com/ar/2014/en/. For further information, please contact:Beata Augenblick, Investor RelationsTel: +46-18 780 88 50, E-mail: ir@orexo.com  About OrexoOrexo is an integrated pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, Zubsolv® sublingual tablets, for maintenance

    Orexo’s annual report for 2012 released

    Orexo’s annual report for the 2012 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com . For further information, please contact:Beata Augenblick, Investor RelationsTel: +46-18 780 88 50E-mail: beata.augenblick@orexo.com About OrexoOrexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media